Literature DB >> 20392343

Preventing the next generation of extensively drug-resistant tuberculosis.

Y Ben Amor1, M S Day, N W Schluger.   

Abstract

Multidrug-resistant and extremely drug-resistant tuberculosis strains threaten to become an intractable problem. Misuse of antibiotics and inadequacy of diagnostic tools have fostered drug resistance. Effective diagnostic technology would eliminate this problem, but it remains unavailable in high-burden areas. New drugs with novel targets may help combat drug resistance. However, if added singly to existing combination regimens, resistance will increase. To protect the efficacy of a new drug, it should first be used only as a second-line drug, in cases that have undergone drug susceptibility testing. Widespread use of new drugs as first-line agents would follow with the dawn of a new rapid diagnostic era.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392343

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  3 in total

1.  Use of eCompliance, an innovative biometric system for monitoring of tuberculosis treatment in rural Uganda.

Authors:  Sarah Jane Snidal; Genevieve Barnard; Emmanuel Atuhairwe; Yanis Ben Amor
Journal:  Am J Trop Med Hyg       Date:  2015-04-06       Impact factor: 2.345

2.  The need to accelerate access to new drugs for multidrug-resistant tuberculosis.

Authors:  Helen S Cox; Jennifer J Furin; Carole D Mitnick; Colleen Daniels; Vivian Cox; Eric Goemaere
Journal:  Bull World Health Organ       Date:  2015-05-15       Impact factor: 9.408

3.  Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.

Authors:  Daniel Wirth; Ramesh Dass; Robert Hettle
Journal:  BMC Health Serv Res       Date:  2017-03-08       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.